Los resultados de un nuevo estudio ponen en entredicho la creencia generalizada sobre cuándo aparecieron los primeros animales de la Tierra. Según este estudio, el punto de la evolución en el cual entraron en escena los animales corresponde a un momento hasta 200 millones de a&n …
Los primeros animales de la Tierra surgieron mucho antes de lo creído Read More »
El envejecimiento es un proceso universal, pero su ritmo y sus mecanismos biológicos difieren sustancialmente entre individuos y especies. Los perros domésticos constituyen un modelo especialmente útil para investigar la biología del envejecimiento, ya que su esp …
¿Por qué los perros más grandes envejecen más rápido? Read More »
Algunas plantas son tan pequeñas que podemos tenerlas en tiestos del tamaño de tazas. Pero estas resultan gigantes en comparación con la planta de la fotografía, tan pequeña que cabe en la punta de un lápiz. Estas minúsculas plantas pertenecen a la fa …
The disclosure—which came ahead of a presentation of data from the Phase 1 Breakfree-2 study at the ACTRIMS-ECTRIMS meeting—follows Bristol Myers Squibb’s late summer revelation that it had paused certain trials of zolacabtagene autoleucel.
BMS reveals death from septic pneumonia of multiple sclerosis patient in CAR T trial Read More »
A combination of Tango Therapeutics’ vopimetostat and Revolution Medicines’ recently approved Rasonque led to a response rate of 82% in an ongoing Phase 1/2 trial—a drop from 92% that was reported in June in fewer patients.
Amazon, Google, Meta and other employers agreed to reform their prior authorization policies for their self-funded health plans, which provide coverage for millions of Americans.
Five major companies pledge faster, electronic prior authorizations Read More »
RNAi specialist Alnylam Pharmaceuticals will advance the Huntington’s disease drug brezosiran into a placebo-controlled study in 2027 once regulatory alignment is achieved.
Alnylam plans pivotal trial as Huntington’s drug notches ‘best-in-class knockdown’ Read More »
After cardiac safety signals led to a full clinical hold on Aardvark Therapeutics’ studies of ARD-101, the biotech conducted an additional safety study, in which no cardiac events were detected. Aardvark plans to resume testing the candidate next year.
FDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns Read More »
More than 4,000 people across the medtech sector met in Boston for one of the industry’s biggest events of the year. Catch up on all the conference news in MedTech Dive’s roundup.
Medtech leaders discuss AI, cybersecurity and M&A at AdvaMed’s The MedTech Conference Read More »
Gilead Sciences has picked up a new inflammatory disease program from China’s PepStar Therapeutics to pair with the Phase 2 inflammatory bowel disease asset emvistegrast.
Gilead shops in IL-23, inking $1.3B upfront I&I deal with China’s PepStar Read More »
